
    
      This trial is aimed at evaluating the effectiveness of ultra-low dose Bevacizumab plus
      Temozolomide for recurrent high-grade gliomas. And, this trial is approved by medical ethics
      committee of Hebei Yanda Hospital.Researchers will conduct thsi trial from 2015/05 to
      2018/05, and 30 recurrent high-grade glioma patients will be recruited. Patients who are
      recruited will get treatment of ultra-low dose Bevacizumab plus Temozolomide in ether Hebei
      Yanda Hospital or Beijing Tiantan hospital, and get follow-ups from clinicians.
    
  